ritonavir

Ritonavir (ABT 538) is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.

Ritonavir metabolite is a Ritonavir metabolite, which is a inhibitor of HIV protease.

Ritonavir-13C-d3 the 13C and deuterated compound of Ritonavir. Ritonavir has a CAS number of 155213-67-5. Ritonavir is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.

Hydroxy ritonavir, a metabolite of ritonavir, functions as an inhibitor of the HIV protease, thereby serving as a treatment for HIV infection and AIDS [1].

Lopinavir (ABT-378) is a peptidomimetic HIV protease inhibitor effective against HIV protease with the Val 82 mutation. It is less affected by serum protein binding compared to the structurally related drug ritonavir.

CYP3A4-IN-2 is a specific inhibitor of cytochrome P450 3A4 (CYP3A4) (IC50: 0.055 μM). As a ritonavir analogue with a more hydrophobic R2 side group, CYP3A4-IN-2 exhibits stronger inhibition than ritonavir and is capable of acting as an immunosuppressive and antiviral agent.

CYP3A4-IN-3 is a specific, highly affinity cytochrome P450 3A4 (CYP3A4) (cytochrome P450 3A4 (CYP3A4)) inhibitor (IC50: 0.075 μM). CYP3A4-IN-3 is an analogue of ritonavir with a simpler structure and twice as much inhibition as ritonavir. CYP3A4-IN-3 can be used as an antiviral agent and immunosuppressant.

Ureidovaline is an intermediate in the Ritonavir synthesis.

Paritaprevir (ABT450) is an inhibitor of non-structural protein 3 4A protease with EC50 values of 1 and 0.21 nM for HCV 1a and HCV 1b, respectively.

Paritaprevir dihydrate (ABT-450), a highly effective and orally administered antiviral, acts as a non-structural protein 3/4A (NS3/4A) protease inhibitor, displaying EC50 values of 1 and 0.21 nM against HCV genotypes 1a and 1b, respectively. Additionally, it functions as a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Primarily metabolized by cytochrome P450 (CYP) 3A, its plasma concentration and half-life are significantly increased when administered with Ritonavir, a CYP450 inhibitor [1] [2] [3] [4].

Lopinavir-d8 is a deuterated compound of Lopinavir. Lopinavir has a CAS number of 192725-17-0. Lopinavir is a peptidomimetic HIV protease inhibitor that retains activity against HIV protease with the Val 82 mutation. Lopinavir is less affected by binding to serum proteins than the structurally-related drug ritonavir.